Residual DCIS Versus No Residual Breast Tumor After Neoadjuvant Chemotherapy in ypN0 Breast Cancer: A Retrospective Clinical, MRI, and Survival Comparison
Residuales DCIS versus kein residualer Brusttumor nach neoadjuvanter Chemotherapie bei ypN0-Brustkrebs: retrospektiver klinischer, MRT- und Überlebensvergleich
Cancers · 29.10.2026 · 18 (21) · 3491
DOI: 10.3390/cancers18213491 ↗Auf einen Blick
Bei 175 Patient:innen mit ypN0 nach neoadjuvanter Chemotherapie unterschied sich das Überleben zwischen ypTis und ypT0 nicht signifikant. Residuales DCIS war jedoch mit HER2-Positivität und MRT-Satellitenherden assoziiert.
Fragestellung
Unterscheiden sich klinische Merkmale, MRT-Befunde, Behandlung und Überleben zwischen ypTis und ypT0 nach neoadjuvanter Chemotherapie bei ypN0-Brustkrebs?
Methode
Einzelzentrische retrospektive Studie mit Patient:innen mit Stadium II–III nach NAC und definitiver Operation zwischen 2019 und 2023; Vergleich per logistischen Regressionsanalysen sowie Kaplan–Meier und Log-Rank-Test.
Ergebnisse
175 Patient:innen: 139 mit ypT0 und 36 mit ypTis. HER2-Positivität (OR 2,50; 95 %-KI 1,05–5,93) und MRT-Satellitenherde (OR 2,41; 95 %-KI 1,12–5,16) waren mit ypTis assoziiert. DFS und OS unterschieden sich nicht signifikant.
Einschränkungen
Einzelzentrum; nur 36 Patient:innen mit ypTis und wenige Outcome-Ereignisse.
Schlussfolgerung der Autor:innen
Residuales DCIS war nach NAC nicht mit statistisch signifikanten Unterschieden in DFS oder OS assoziiert. Die Autor:innen betonen jedoch, dass daraus keine prognostische Gleichwertigkeit abgeleitet werden kann und die Ergebnisse vorsichtig zu interpretieren sind.
Kernaussagen
- 175 Patient:innen; medianes Follow-up 51 Monate
- HER2-Positivität und MRT-Satellitenherde mit ypTis assoziiert
- DFS und OS zwischen ypTis und ypT0 nicht signifikant verschieden
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 29.10.2026. Verfasst von Özlem Mermut und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Health Sciences Turkey, Istanbul Training and Research Hospital, 34098 Istanbul, Turkey. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: The prognostic significance of residual ductal carcinoma in situ (ypTis) compared with no residual tumor in the breast (ypT0) after neoadjuvant chemotherapy (NAC) remains uncertain. We compared clinicopathological, MRI, treatment, and survival outcomes between these groups.
Methods
This single-center retrospective study included consecutive patients with stage II–III breast cancer who achieved ypN0 and ypT0/is status after NAC and definitive surgery between 2019 and 2023. Univariable and multivariable logistic regression analyses were performed to identify factors associated with ypTis. DFS and OS were assessed using Kaplan–Meier analysis and log-rank tests.
Results
Among 175 patients, 139 (79.4%) had ypT0 and 36 (20.6%) had ypTis. Median follow-up was 51 months. Clinical T-stage distribution differed significantly between groups (p = 0.010), with cT4 disease in 13.9% of ypTis versus 2.2% of ypT0 patients. HER2 positivity and MRI-detected satellite foci were more frequent in the ypTis group. In multivariable analysis, HER2 positivity (OR 2.50, 95% CI 1.05–5.93; p = 0.038), and MRI-detected satellite foci (OR 2.41, 95% CI 1.12–5.16; p = 0.024) were associated with ypTis. Local recurrence occurred in 3/36 (8.3%) ypTis and 1/139 (0.7%) ypT0 patients. DFS did not differ significantly between groups (5-year estimates: 78.7% vs. 78.9%; p = 0.860). OS also showed no significant difference (5-year estimates: 96.8% vs. 87.3%; p = 0.320).
Conclusions
Residual DCIS was not associated with statistically significant differences in DFS or OS following NAC. However, these findings do not establish prognostic equivalence and should be interpreted cautiously given the limited number of ypTis patients and outcome events.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Health Sciences Turkey, Istanbul Training and Research Hospital, 34098 Istanbul, Turkey.
- Department of Medical Oncology, University of Health Sciences Turkey, Istanbul Training and Research Hospital, 34098 Istanbul, Turkey.
- Department of Nuclear Medicine, University of Health Sciences Turkey, Istanbul Training and Research Hospital, 34098 Istanbul, Turkey.
- Department of Pathology, University of Health Sciences Turkey, Istanbul Training and Research Hospital, 34098 Istanbul, Turkey.
- Department of Radiology, University of Health Sciences Turkey, Istanbul Training and Research Hospital, 34098 Istanbul, Turkey.
- Department of General Surgery, University of Health Sciences Turkey, Istanbul Training and Research Hos pital, 34098 Istanbul, Turkey.
ORCID-Profile: Özlem Mermut, Esra Arslan
Zitieren
APA
Mermut, Ö., Yalçın, B., Gürsu, R. U., Arslan, E., Battal Havare, S., Ata, E. S., Cengiz Gökmen, M. B., & Can Trabulus, D. (2026). Residual DCIS Versus No Residual Breast Tumor After Neoadjuvant Chemotherapy in ypN0 Breast Cancer: A Retrospective Clinical, MRI, and Survival Comparison. Cancers, 18(21), 3491. https://doi.org/10.3390/cancers18213491
Vancouver
Mermut Ö, Yalçın B, Gürsu RU, Arslan E, Battal Havare S, Ata ES, et al. Residual DCIS Versus No Residual Breast Tumor After Neoadjuvant Chemotherapy in ypN0 Breast Cancer: A Retrospective Clinical, MRI, and Survival Comparison. Cancers. 2026;18(21):3491. doi:10.3390/cancers18213491
BibTeX
@article{Mermut2026,
author = {Mermut, Özlem and Yalçın, Berrin and Gürsu, Rıza Umar and Arslan, Esra and Battal Havare, Semiha and Ata, Emine Sevcan and Cengiz Gökmen, Merve Büşra and Can Trabulus, Didem},
title = {Residual DCIS Versus No Residual Breast Tumor After Neoadjuvant Chemotherapy in ypN0 Breast Cancer: A Retrospective Clinical, MRI, and Survival Comparison},
journal = {Cancers},
year = {2026},
volume = {18},
number = {21},
pages = {3491},
doi = {10.3390/cancers18213491}
}
EUVIMED